ConvaTec Group (LON:CTEC) Insider Jonny Mason Sells 291,149 Shares of Stock

ConvaTec Group PLC (LON:CTEC) insider Jonny Mason sold 291,149 shares of the company’s stock in a transaction on Monday, March 16th. The shares were sold at an average price of GBX 234, for a total value of £681,288.66.

ConvaTec Group Price Performance

Shares of LON CTEC opened at GBX 233.80 on Wednesday. The company has a debt-to-equity ratio of 106.19, a quick ratio of 0.96 and a current ratio of 1.53. ConvaTec Group PLC has a 52 week low of GBX 209.40 and a 52 week high of GBX 311.20. The stock has a market capitalization of £4.56 billion, a P/E ratio of 27.19, a PEG ratio of 0.93 and a beta of 0.76. The stock’s fifty day moving average is GBX 235.34 and its 200 day moving average is GBX 236.69.

Wall Street Analysts Forecast Growth

Several equities analysts have commented on the stock. Citigroup reissued an “outperform” rating and issued a GBX 315 target price on shares of ConvaTec Group in a report on Thursday, March 5th. Stifel Nicolaus reiterated a “buy” rating and set a GBX 315 price target on shares of ConvaTec Group in a research report on Wednesday, March 11th. Finally, Berenberg Bank lifted their price objective on shares of ConvaTec Group from GBX 330 to GBX 340 and gave the company a “buy” rating in a research note on Thursday, January 22nd. Eight equities research analysts have rated the stock with a Buy rating, According to MarketBeat.com, the company has an average rating of “Buy” and a consensus target price of GBX 319.

About ConvaTec Group

ConvaTec Group PLC engages in the development, manufacturing, and sale of medical products, services, and technologies in Europe, North America, and internationally. The company offers advanced wound dressings and skin care products for the management of acute and chronic wounds resulting from various conditions, such as diabetes, and acute conditions resulting from traumatic injury and burns. It also provides ostomy care solutions, including devices, accessories, and services for people with a stoma resulting from colorectal cancer, inflammatory bowel disease, and bladder cancer.